{"schema_version":"secwatch.filing_event.v1","accession":"0000872589-25-000026","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2025-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.415953+00:00","generated_at":"2026-05-17T02:05:34.226137+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Regeneron Q3'25: Revenue $3.75B (+1%), GAAP EPS $13.62, Non-GAAP EPS $11.83; EYLEA sales down 28%","bullets":["Total revenue $3.754B (+1% YoY); GAAP EPS $13.62 (+18%), non-GAAP EPS $11.83 (-5%).","Dupixent global net sales (Sanofi) up 27% to $4.86B; total EYLEA HD+EYLEA U.S. down 28% to $1.11B.","FDA approved Libtayo for adjuvant CSCC; positive Phase 3 data for cemdisiran in myasthenia gravis and DB-OTO gene therapy in hearing loss.","2025 guidance revised: GAAP R&D $5.68-5.75B, GAAP SG&A $2.775-2.845B, gross margin about 82%, ETR about 14%."],"urls":{"canonical":"https://secwatch.observer/filing/0000872589-25-000026","json":"https://secwatch.observer/filing/0000872589-25-000026.json","markdown":"https://secwatch.observer/filing/0000872589-25-000026.md","text":"https://secwatch.observer/filing/0000872589-25-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000026/0000872589-25-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000026/regn-20251028.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:05:34.226137+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}